A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Ularitide (Primary)
- Indications Decompensated heart failure
- Focus Registrational; Therapeutic Use
- Sponsors PDL BioPharma
- 16 Aug 2017 Status changed from recruiting to discontinued.
- 28 Jul 2017 This trial has been suspended in Austria.
- 24 Jun 2011 This trial is recruiting in Lithuania, but has prematurely ended in Finland.